Nektar Therapeutics Accounts Receivable, Allowance for Credit Loss
Nektar Therapeutics (NKTR) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2022-05-06
- 2022-03-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2021-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2021-09-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2021-06-30: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 |
| 2021-12-31 | $0.00 10-Q · filed 2022-05-06 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-05 |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-09 |
| 2012-06-30 | $0.00 10-Q · filed 2012-08-09 |
| 2012-03-31 | $0.00 10-Q · filed 2012-05-04 |
| 2011-12-31 | $0.00 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |